The study’s main results, published in 2005 and in 2017, indicated that one year of treatment with trastuzumab had a significant and sustained benefit in preventing cancer recurrence and improving overall survival among this group of patients.
Coordinated by BIG, the Institut Jules Bordet – Clinical Trials Support Unit, and Frontier Science Scotland in collaboration with Roche, HERA involved the participation of 27 BIG collaborative groups and helped accelerate the approval of trastuzumab, becoming a standard treatment for HER2-positive breast cancer.